Likmez (Metronidazole) Patent Expiration, LOE Window & CMS Spending

Likmez (Metronidazole) by Saptalis: FDA Orange Book LOE 2039-10-04, 35 AB generics, $1.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSaptalis
FDA Application & PathwayN216755 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-10-04
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors35
2024 CMS Total Public Spend$1.1M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel